vs
Astrana Health, Inc.（ASTH）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是Astrana Health, Inc.的1.5倍（$1.4B vs $950.5M），瑞思迈净利率更高（27.6% vs 0.7%，领先26.9%），Astrana Health, Inc.同比增速更快（42.9% vs 11.0%），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 7.8%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
ASTH vs RMD — 直观对比
营收规模更大
RMD
是对方的1.5倍
$950.5M
营收增速更快
ASTH
高出31.9%
11.0%
净利率更高
RMD
高出26.9%
0.7%
两年增速更快
ASTH
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $1.4B |
| 净利润 | $6.6M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | 1.9% | 34.6% |
| 净利率 | 0.7% | 27.6% |
| 营收同比 | 42.9% | 11.0% |
| 净利润同比 | 184.4% | 13.9% |
| 每股收益（稀释后） | $0.12 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHRMD
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.4B | ||
| Q4 25 | $950.5M | $1.4B | ||
| Q3 25 | $956.0M | $1.3B | ||
| Q2 25 | $654.8M | $1.3B | ||
| Q1 25 | $620.4M | $1.3B | ||
| Q4 24 | $665.2M | $1.3B | ||
| Q3 24 | $478.7M | $1.2B |
净利润ASTHRMD
| Q2 26 | — | $392.6M | ||
| Q1 26 | — | $398.7M | ||
| Q4 25 | $6.6M | $392.6M | ||
| Q3 25 | $373.0K | $348.5M | ||
| Q2 25 | $9.4M | $379.7M | ||
| Q1 25 | $6.7M | $365.0M | ||
| Q4 24 | $-7.8M | $344.6M | ||
| Q3 24 | $16.1M | $311.4M |
毛利率ASTHRMD
| Q2 26 | — | 61.8% | ||
| Q1 26 | — | 62.2% | ||
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | — | 58.6% | ||
| Q3 24 | — | 58.6% |
营业利润率ASTHRMD
| Q2 26 | — | 34.6% | ||
| Q1 26 | — | 34.9% | ||
| Q4 25 | 1.9% | 34.6% | ||
| Q3 25 | 2.0% | 33.4% | ||
| Q2 25 | 3.1% | 33.7% | ||
| Q1 25 | 3.3% | 33.0% | ||
| Q4 24 | 0.1% | 32.5% | ||
| Q3 24 | 5.9% | 31.6% |
净利率ASTHRMD
| Q2 26 | — | 27.6% | ||
| Q1 26 | — | 27.9% | ||
| Q4 25 | 0.7% | 27.6% | ||
| Q3 25 | 0.0% | 26.1% | ||
| Q2 25 | 1.4% | 28.2% | ||
| Q1 25 | 1.1% | 28.3% | ||
| Q4 24 | -1.2% | 26.9% | ||
| Q3 24 | 3.4% | 25.4% |
每股收益（稀释后）ASTHRMD
| Q2 26 | — | $2.68 | ||
| Q1 26 | — | $2.74 | ||
| Q4 25 | $0.12 | $2.68 | ||
| Q3 25 | $0.01 | $2.37 | ||
| Q2 25 | $0.19 | $2.58 | ||
| Q1 25 | $0.14 | $2.48 | ||
| Q4 24 | $-0.14 | $2.34 | ||
| Q3 24 | $0.33 | $2.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $1.4B |
| 总债务越低越好 | — | $663.8M |
| 股东权益账面价值 | $779.3M | $6.3B |
| 总资产 | $2.2B | $8.5B |
| 负债/权益比越低杠杆越低 | — | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资ASTHRMD
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.7B | ||
| Q4 25 | $429.5M | $1.4B | ||
| Q3 25 | $463.4M | $1.4B | ||
| Q2 25 | $342.1M | $1.2B | ||
| Q1 25 | $260.9M | $932.7M | ||
| Q4 24 | $290.8M | $521.9M | ||
| Q3 24 | $350.3M | $426.4M |
总债务ASTHRMD
| Q2 26 | — | $663.8M | ||
| Q1 26 | — | $664.1M | ||
| Q4 25 | — | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | — | $662.9M | ||
| Q3 24 | — | $667.6M |
股东权益ASTHRMD
| Q2 26 | — | $6.3B | ||
| Q1 26 | — | $6.5B | ||
| Q4 25 | $779.3M | $6.3B | ||
| Q3 25 | $775.5M | $6.1B | ||
| Q2 25 | $765.5M | $6.0B | ||
| Q1 25 | $745.4M | $5.5B | ||
| Q4 24 | $712.7M | $5.3B | ||
| Q3 24 | $704.6M | $5.2B |
总资产ASTHRMD
| Q2 26 | — | $8.5B | ||
| Q1 26 | — | $8.8B | ||
| Q4 25 | $2.2B | $8.5B | ||
| Q3 25 | $2.2B | $8.3B | ||
| Q2 25 | $1.4B | $8.2B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.4B | $7.1B | ||
| Q3 24 | $1.3B | $7.2B |
负债/权益比ASTHRMD
| Q2 26 | — | 0.11× | ||
| Q1 26 | — | 0.10× | ||
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | — |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | — |
| 自由现金流率自由现金流/营收 | -0.6% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | -0.44× | — |
| 过去12个月自由现金流最近4个季度 | $104.5M | — |
8季度趋势，按日历期对齐
经营现金流ASTHRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-2.9M | $339.7M | ||
| Q3 25 | $10.0M | $457.3M | ||
| Q2 25 | $90.9M | $538.8M | ||
| Q1 25 | $16.6M | $578.7M | ||
| Q4 24 | $-10.9M | $308.6M | ||
| Q3 24 | $34.0M | $325.5M |
自由现金流ASTHRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-6.0M | $311.2M | ||
| Q3 25 | $7.4M | $414.4M | ||
| Q2 25 | $89.5M | $508.2M | ||
| Q1 25 | $13.6M | $557.9M | ||
| Q4 24 | $-13.5M | $288.0M | ||
| Q3 24 | $31.7M | $307.7M |
自由现金流率ASTHRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -0.6% | 21.9% | ||
| Q3 25 | 0.8% | 31.0% | ||
| Q2 25 | 13.7% | 37.7% | ||
| Q1 25 | 2.2% | 43.2% | ||
| Q4 24 | -2.0% | 22.5% | ||
| Q3 24 | 6.6% | 25.1% |
资本支出强度ASTHRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 2.0% | ||
| Q3 25 | 0.3% | 3.2% | ||
| Q2 25 | 0.2% | 2.3% | ||
| Q1 25 | 0.5% | 1.6% | ||
| Q4 24 | 0.4% | 1.6% | ||
| Q3 24 | 0.5% | 1.5% |
现金转化率ASTHRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -0.44× | 0.87× | ||
| Q3 25 | 26.69× | 1.31× | ||
| Q2 25 | 9.65× | 1.42× | ||
| Q1 25 | 2.48× | 1.59× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | 2.11× | 1.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
RMD
暂无分部数据
